Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Summary

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.

Timeline

Start

2024-05-21

Primary completion

2026-06-01

Completion

2026-09

Drugs

Indications